Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SIRT (TheraSphere) plus capecitabine in operable intrahepatic cholangiocarcinoma
2021-001575-16Phase 2Active
- Sponsor
- Centre Eugène Marquis
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of yttrium-90 and capecitabine in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Centre Eugène Marquis. Primary endpoint: Adequate surgical margins (primary). Started Sep 2021; status: active.
02
Drugs
yttrium-90capecitabine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2021-001575-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001575-16.